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Background: Despite remarkable advances in genetic testing, many adults with syndromic epilepsy remain without
a molecular diagnosis. The challenge in providing genetic testing for this patient population lies in the extensive
genetic heterogeneity associated with epilepsy. Even for the subset of epilepsy patients that present with a
defining feature, such as microcephaly, the number of possible genes that would require interrogation by Sanger
sequencing is extensive and often prohibitively expensive.
Case presentation: We report a family of French Canadian descent with four adult children affected with severe
intellectual disability, epilepsy and microcephaly born to consanguineous parents and evaluated by the Genetics
Service to provide informed genetic counseling to unaffected family members regarding possible recurrence risks.
We used whole-exome sequencing (WES) of DNA from one affected sibling as a first-line diagnostic tool and
compared the prioritization of variants using two strategies: 1) focusing on genes with homozygous variants; and,
2) focusing on genes associated with microcephaly. Both approaches prioritized the same homozygous novel
frameshift mutation (p.Arg608Serfs*26) in WDR62, a gene known to cause autosomal recessive primary microcephaly.
Sanger sequencing confirmed the presence of the homozygous mutation in the other three affected siblings.
Conclusions: WES and subsequent filtering of the rare variants in a single affected family member led to the rapid
and cost-effective identification of a novel homozygous frameshift mutation in WDR62, thereby explaining the severe
neurodevelopmental disorder in this family and facilitating genetic counseling. Our findings support WES as an
effective first-line diagnostic tool in families presenting with rare genetically heterogeneous neurological disorders.
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Although up to 70% of patients with epilepsy have an
underlying genetic cause [1], most patients with epilepsy
will not receive a molecular diagnosis. Genetic testing
for epilepsies is challenging since genetic heterogeneity
for this group of conditions is significant. For instance,
epilepsy can be caused by mutations in over 260 genes* Correspondence: kboycott@cheo.on.ca
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stated.and an accurate diagnosis can be particularly difficult with
nonspecific epilepsy phenotypes [2]. Even when epilepsy
is associated with additional features, such as micro-
cephaly, the number of genes potentially responsible can
still be significant and assessing each gene in turn by
Sanger sequencing would be time-consuming and ex-
pensive. However, establishing a molecular diagnosis is
important for informed genetic counseling, prenatal test-
ing, insight into natural history and increasingly for
therapeutic management as there are now many in-
stances where medications are tailored based on mo-
lecular results [3-5].
Whole exome sequencing (WES) has emerged as a
very successful tool for novel disease gene discovery [6]ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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heterogeneous disorders is being established. Both a
WES approach and the application of targeted panels of
channelopathy or encephalopathy genes have been suc-
cessful in identifying the molecular cause for many pa-
tients with rare epilepsies [2,7]. In addition, WES may
offer a rapid and less expensive first line test to establish
a molecular diagnosis for disabled patients residing in
remote areas where ready access to standard diagnostic
assessments can be more challenging. We report here
the utility of WES as the initial diagnostic tool for a con-
sanguineous family with four affected adult children with
epilepsy, microcephaly and severe intellectual disability
from a remote area of Canada.
Case presentation
Clinical findings
Four affected siblings (two females and two males) from
a consanguineous French Canadian family presentedFigure 1 WES identifies a novel frameshift mutation in WDR62. (A) Fa
unaffected family members (open symbols). Squares represent males, circle
WES (black arrow). (B) WES in Patient II-1 revealed a homozygous single-base
(p.Arg608Serfs*26). (C) The mutation was validated by Sanger sequencing in a
unavailable for this study. The mutation is absent in an unaffected control (W
on chromosome 19q13.12 and contains 32 exons (NM_001083961.1) encodin
as peptide changes (grey). Number sign indicates the compound heterozygo
base pair insertion identified in the French-Canadian family is also shown (redin their 40s and 50s to a satellite genetics clinic for as-
sessment to facilitate genetic counseling for extended
family members (Figure 1A). Two developmentally nor-
mal brothers died in an accidental fire and one living
brother is unaffected. The parents were from an isolated
community and were distantly related. The four siblings
had moderate to severe intellectual disability, epilepsy
and microcephaly (Table 1). A more severe phenotype
was seen in the two male siblings, including medically
refractory seizures, aggression and self-injury. Due to the
difficulty of performing MRI in a remote region and the
long differential diagnosis, DNA was sent for WES as an
initial investigation.
Genetic studies
Genomic DNA was extracted from whole blood obtained
from the four affected individuals using the QIAamp
DNA Blood Kit (Qiagen, CA, USA). DNA from Patient II-
1 underwent WES. Using target capture with the Agilentmily pedigree showing the four affected siblings (solid symbols) and
s females, asterisk denote available DNA. Patient II-1 was selected for
pair insertion (c.1821dupT) in WDR62 producing a frameshift mutation
ll affected siblings (only II-1 and II-2 are shown); parental DNA was
T). (D) Reported WDR62 mutations in MCPH2 families. WDR62 is located
g 1523 amino acids. For clarity, reported WDR62 mutations are annotated
us mutation present in one reported family [15]. The homozygous single-
).
Table 1 Clinical and neuroimaging features of the four MCPH2 patients
Patient II-1 II-2 II-3 II-4
Gender F M M F
Age at assessment (yrs) 59 56 55 53
Clinical features
Height (cm) 158 154 166 154
Height percentile 10-25th <5th 5th 5-10th
Occipito-frontal circumference (cm) 48.5 52 51 48
Occipito-frontal circumference (SD) -4 to -5 SD -2 to -3 SD -3 SD -4 to -5 SD
Sloping forehead + + + +
Intellectual disability Moderate-severe Severe Severe Moderate-severe
Behaviour Pleasant Self injurious behaviour Self injurious behaviour Pleasant
Tone Normal Hypertonia Hypertonia Normal
Sensory exam Normal Normal Normal Normal
Reflexes Normal Hyperreflexia/ankle clonus Hyperreflexia/ankle clonus Normal
Bladder/bowel incontinence +/- +/+ +/+ +/-
Neuroimaging features
Microcephaly + Nd Nd +
Polymicrogyria - Nd Nd -
Cerebellar hypoplasia - Nd Nd -
Cortical thickenng - Nd Nd -
Corpus callosum hypoplasia - Nd Nd -
Abbreviations: F female, M male, nd not determined.
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Santa Clara, CA) and sequencing of 100 bp paired end
reads on Illumina Hiseq, we generated over 15 Gb of se-
quence for the sample such that approximately 90% of the
coding bases of the exome defined by the consensus
coding sequence (CCDS) project were covered by at
least 20 reads. WES data was analyzed as previously de-
scribed [8] and non-synonymous variants (frameshift
and non-frameshift indels, single nucleotide variants
(SNV) including stop-gain and missense SNVs, and
splicing and splicing-extending variants) were identified
as rare when they had a frequency of less than 1% in
the 1000 genomes pilot release (Nov 2010) and in 100
in-house controls. We then compared two approaches
to examine this subset of WES variants (Figure 2).
Following our preliminary filtering steps that identified
183 rare non-synonymous variants, we examined the se-
quencing data for homozygous variants as the pedigree
was consistent with autosomal recessive inheritance and
the parents were distantly related (see Method 1, Figure 2).
WES identified ten exome-wide homozygous variants in-
cluding a rare variant in WDR62, encoding a protein es-
sential to cerebral cortex development and known to
cause microcephaly [9-11] (Figure 1B) and thus felt to be
a strong candidate gene for the disorder in this family.
The WDR62 mutation identified is a novel homozygous
single-base pair insertion NM_001083961.1:c.1821dupT)producing a frameshift mutation (p.Arg608Serfs*26) in
exon 14 (Figure 1C). The protein-truncating mutation is
absent from the 6500 exomes in the NHLBI Exome Vari-
ant Server. We next examined the WES data using a sec-
ond approach to identify all rare variants in genes known
to be associated with epilepsy and microcephaly (see
Method 2, Figure 2); the same mutation in WDR62 was
identified as the only candidate.
The mutation in WDR62 was validated by Sanger se-
quencing in the other three siblings. After the diagno-
sis, unenhanced MRI of the brain was performed in
both sisters and demonstrated microcephaly without
polymicrogyria, cerebellar hypoplasia, cortical thicken-
ing or corpus callosum hypoplasia. Patient II-2 died
suddenly of a cardiac arrest but was not known to have
cardiac disease prior to the fatal event; the family de-
clined an autopsy.
Discussion
Primary autosomal recessive microcephaly (MCPH,
OMIM 251200) is a genetically heterogeneous group of
disorders characterized by congenital microcephaly, cog-
nitive impairment and variable epilepsy [12]. Mutations
in WDR62 are associated with primary microcephaly-2
(MCPH2, OMIM 604317), which is believed to account
for 10% of all cases of MCPH [13]. Clinical features of
MCPH2 include epilepsy, marked cognitive impairment,
Figure 2 Exome sequencing workflow. Exome sequencing was performed on isolated DNA from Patient II-1. The data was filtered to identify
non-synonymous sequence variants including frameshift and non-frameshift indels, single nucleotide variants (SNV) including stop-gain and mis-
sense SNVs, and splicing and splicing-extending variants. Variants with a frequency of less than 1% in the 1000 genomes pilot release (Nov 2010)
and in 100 in-house controls were then identified. The first method of analysis focused on rare homozygous variants (Method 1) and a second,
simpler approach, focused only on rare variants in disease genes known to cause microcephaly/epilepsy (Method 2). Both methods identified the
homozygous mutation in WDR62 as the cause of the neurodevelopmental disorder in this family.
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Radiological features are variable and may include poly-
microgyria, corpus callosum hypoplasia, heterotopias,
pachygyria with cortical thickening, lissencephaly and
schizencephaly, although patients can present with iso-
lated microcephaly [14-18]. To date, 34 families have
been identified with mutations in WDR62, the reported
affected individuals ranging in age from infancy to mid-
teens [14-18].We present here the oldest patients known
to have WDR62 mutations associated with MCPH, pro-
viding additional insight into the natural history and
phenotypic spectrum of this disorder. It is unclear
whether the sudden cardiac death for Patient II-2 is as-
sociated with WDR62 mutations or an unrelated cardiac
event. Of the mutations in WDR62 reported thus far, ap-
proximately half have been frameshift mutations, as de-
scribed here, distributed throughout the gene andpredicted to result in premature truncation of the pro-
tein (Figure 1C).
At least ten genes have been associated with MCPH
[ASPM, MCPH1, WDR62, CDK5RAP2, CASC5, CENPJ,
STIL, CEP135, CEP152 and ZNF335] and are implicated
in proliferation and migration of neuronal progenitors
during embryonic cortical development [19]. Clinical-
radiological features have not been loci-specific and
MCPH patients remain phenotypically indistinguishable
[13]. Thus, conventional molecular testing can be a long
and expensive process and may not yield a diagnosis.
Currently, sequential analysis of the eight clinically
available MCPH genes would total more than $22,000
USD. Alternatively, eight of the ten MCPH genes could
be sequenced as part of a microcephaly panel for
$7,000 USD (www.centogene.com accessed November
6th, 2013, eight genes). Comparatively, WES would
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rently available in clinical laboratories at $5000 USD
per patient, making it a cost-effective solution for
rapid diagnosis in the clinic.
Conclusion
We studied four siblings from a consanguineous French
Canadian family presenting with microcephaly, severe
developmental delay and epilepsy. Given their relatively
nonspecific phenotype which did not suggest a single
likely candidate gene, sequential gene testing was not
undertaken. Alternatively, WES provided a cost-effective
and rapid method to identify the genetic cause of epi-
lepsy and microcephaly in this family. We highlight, that
particularly for patients in remote areas, WES via DNA
blood/saliva offers a non-invasive and readily accessible
method for shortening the diagnostic process for these
patients.
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